Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 1.00 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | VNN1 | O95497 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7832199 | 0.78 | CNR2 (1.00) | CNR2HSD17B14ALDH1A1KDM4EMAPT | |
| SCHEMBL30227109 | 0.78 | CNR2 (1.00) | CNR2HSD17B14ALDH1A1KDM4EMAPT | |
| SCHEMBL28230040 | 0.77 | NPC1 (0.66) | CNR2ALDH1A1KDM4EPOLBCYP3A4 | |
| SCHEMBL13475587 | 0.77 | CNR2 (0.72) | CNR2HSD17B14ALDH1A1CES2KDM4E | |
| SCHEMBL27838449 | 0.77 | CNR2 (0.96) | CNR2HSD17B14ALDH1A1KDM4EMAPT | |
| SCHEMBL1237189 | 0.77 | SRD5A2 (0.79) | CNR2ALDH1A1CES2SRD5A2VNN1 | |
| SCHEMBL13475585 | 0.76 | CNR2 (0.70) | CNR2HSD17B14ALDH1A1CES2KDM4E | |
| SCHEMBL1044812 | 0.75 | SRD5A2 (0.83) | CNR2CES2SRD5A2VNN1TDP1 | |
| SCHEMBL1343443 | 0.75 | CNR2 (0.78) | CNR2HSD17B14ALDH1A1KDM4EMAPT | |
| Quinoline SCHEMBL28604857 | 0.73 | CNR2 (0.57) | CNR2ALDH1A1CES2VNN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020132812-A1 | Oral hypoglycaemic agents | NOVO NORDISK A/S (DK) | 2002-09-19 | — | — | US | disclosed |
| WO-2002038559-A1 | 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS | NOVO NORDISK A/S (DK) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132812-A1 | Oral hypoglycaemic agents | SLC5A2, GPR119, SLC5A1 | CNR2 2676/4885HSD17B14 194/4885ALDH1A1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.